Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 4, 2004 - Issue 3
Submit an article Journal homepage
61
Views
5
CrossRef citations to date
0
Altmetric
Drug Evaluation

Divalproex sodium in the treatment of adults with bipolar disorder

Lori L Davis University of Alabama at Birmingham, Birmingham, AL and Co-ordinator of Research and Development at the Veterans Affairs Medical Center, 3701 Loop Road East, Tuscaloosa, AL, USA. [email protected]
,
Raela Williams Veterans Affairs Medical Center, Tuscaloosa, AL, USA. [email protected]
&
Marshall Cates Samford University McWhorter School of Pharmacy, Birmingham, AL and Clinical Pharmacy Specialist in Psychiatry at Veterans Affairs Medical Center, Tuscaloosa, Alabama, USA. [email protected]
Pages 349-362 | Published online: 10 Jan 2014

References

  • Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Rychiatry59, 530–537 (2002).
  • Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. PFchiatry60, 261–269 (2003).
  • Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a re-examination. Am. j PFchiatry157, 1925–1932 (2000).
  • Rihmer Z, Kiss K. Bipolar disorders and suicidal behavior. Bipo/arDisar/ 4(1), 21–25 (2002).
  • Akiskal HS, Walker P, Puzantian VR, King D, Rosenthal TL, Dranon M. Bipolar outcome in the course of depressive illness: phenomenologic, familial, and pharmacologic predictors. j Affect. Disond 5(2), 115–128 (1983).
  • Weissman MM, Bland RC, Canino GJ et al. Cross-national epidemiology of major depression and bipolar disorder. JAIVIA 276,293–299 (1996).
  • Weissman MM, Bruce ML, Leaf PJ, Floric LP, Holzor C III. Affective disorders. In: Psychiatric Disoirlers in America: The Epidemiological Catchment Ama Study Robins LN, Reiger DA (Eds). The Free Press, NY, USA, 53–80 (1991).
  • Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H, Hirschfeld R Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders.' Affect Disoni. 59, S5—S30 (2000).
  • Angst J. The emerging epidemiology of hypomania and bipolar II disorder. j Affect. Disarl. 50,143–151 (1998).
  • Hirschfeld R, Calabrese JR, Weissman M et al. Prevalence of bipolar spectrum in US adults. Eur. Neuropsychopharmacol 12 (Suppl. 3), S218 (2002).
  • World Health Organization. The World Health Report. World Health Organization. Geneva, Switzerland (1999).
  • Yerevanian BI, Koek RJ, Mintz J. Lithium, anticonvulsants and suicidal behavior in bipolar disorder. j Affect. Disond 73, 223–228 (2003).
  • Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAIVIA 290, 1467–1473 (2003).
  • Hirschfeld RMA, Bowden CL, Gitlin MJ et alfor the Work Group on Bipolar Disorder. Practice guideline for the treatment of patients with bipolar disorder. Am. PTchiatry159, 1–50 (2002). American Psychiatric Association 2002 Treatment Guidelines for bipolar disorder based on published evidence.
  • Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G. Lithium for maintenance treatment of mood disorders. In: The Cochrane Library Update Software. Issue I. Oxford, UK (2002).
  • Bowden CL, Calabrese JR, McElroy SL et al for the Divalproex Maintenance Study Group. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch. Gen. Bychiatry57, 481–489 (2000).
  • ••Pivotal controlled maintenance trial ofdivalproex for bipolar disorder.
  • Tohen M, Jacobs TG, Grundy SL et alfor the Olanzapine HGGW Study Group. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch. Gen. PTchiatry57, 841–849 (2000).
  • ••Pivotal controlled study of olanzapine for bipolar mania.
  • Keck PE, Versiani M, Potkin S, West SA, Giller E, Ice K and the Ziprasidone in Mania Study Group. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am. J Rychiatry160, 741–748 (2003). Pivotal controlled study of ziprasidone for bipolar mania.
  • Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin. Neuropharmacol. 2(3), 176–180 (2003). Pivotal controlled study of risperidone for bipolar mania.
  • Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am. J Psychiatry 159,1146–1154. (2002).
  • Bowden CL, Calabrese JR, Sachs G et alfor the Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry 60, 392–400 (2003). Pivotal controlled maintenance trial of lamotrigine for bipolar disorder.
  • Calabrese JR, Shelton MD, Rapport DJ, Kimmel SE, Elhaj O. Long-term treatment of bipolar disorder with lamotrigine. Gun. Psychiatry 63 (Suppl 10), S18—S22 (2002).
  • Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD, for the Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Gun. fiych. 60,79-88 (1999).
  • ••Pivotal controlled trial of lamotrigine for bipolar depression.
  • Calabrese JR, Suppes T, Bowden CL et al for the Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Gun. Psych. 61, 841–850 (2000).
  • ••Pivotal controlled trial of lamotrigine for rapid cycling bipolar disorder.
  • Meunier G, Caraz G, Meunier Y, Eymard P, Aimard M. Properietes pharmacodynamiques de l'acide n-dipropylacetique. Therapie 18,435–438 (1963).
  • Lambert PA, Cavaz G, Borselli S, Carrel S. Action neuropsychotrope d'un nouvel antiepileplique: le depamide. Ann. Med Psychol. 1,707–710 (1966).
  • Lambert PA. Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In:Anticonvulsants in Affective Disorrlers. Emrich HM, Okuma T, Muller AA (Eds). Excerpta Medica, Amsterdam, The Netherlands, 33–44 (1984).
  • Zarate CA, Tohen M, Narendran R et al. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. J Gun. Psychiatry 60,232–236 (1999).
  • Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JR The expert consensus guideline series: Medication treatment of bipolar disorder 2000. Postgrad. Med. April, 1–104 (2000).
  • Davis LL, Ryan W, Adinoff B, Petty E Comprehensive review of the psychiatric uses of valproate. j Gun. PTchopharmacology20, S1—S17 (2002).
  • ••The most comprehensive review of divalproex for psychiatric disorders, including articles that required translation into English.
  • Tunnicliff G. Actions of sodium valproate on the central nervous system. J. Physiol. Pharmacol. 50(3), 347–365 (1999).
  • Maas M, Calabrese JR. Mechanisms of action of valproate in affective disorders. In: Anticonvulsants in Mood Disorders: Joffe RT, Calabrese JR (Eds). Marcel Dekker Inc., NY, USA, 93–110 (1994).
  • Chapman A, Keane PE, Meldrum BS, Simiand J, Vemieres JC. Mechanism of anticonvulsant action of valproate. Frog. Neurobiol. 19,315–359 (1982).
  • Loscher W Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Progress Neumbiol. 58,31–42 (1999).
  • McLean MJ, MacDonald RL. Sodium valproate but ethosuximate, produces use and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol. Exp. Ther 237, 1001–1011 (1986).
  • Francesschetti S, Hamon B, Heinenmann U. The action of valproate on spontaneous epileptiform activity in the absence of synaptic transmission and on the evoked changes on Kai and (K) in the hippocampal slice. Brain Res. 386,1–11 (1986).
  • Schechter PJ, Trainer Y, Grove J. Effect of N-dipropylacetate on amino acid concentration in mouse brain: correlation with anticonvulsant activity. I Neurochem. 3,1325–1327 (1978).
  • Whitton PS, Fowler U. The effect of valproic acid on 5-hydroxytryptamine and 5-hydroxyindoleacetic acid concentration in hippocampal dialysates in vivo. Eur Pharmacol. 200,167–169 (1991).
  • Shulda GS. Combined lithium and valproate treatment and subsequent withdrawal: serotonergic mechanism of their interaction in discrete brain regions. Progr Neuropsychopharm. Biol. Bychiatry 9, 153–156 (1958).
  • Biggs CS, Pearce BR, Fowler LI Whitton PS. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain — an in vivo microdialysis study. I Neurochem. 59, 1702–1708 (1992).
  • Kempf E, Mack G, Schleef C, Mandel P. Effect of valproic acid on brain serotonin metabolism in isolated and grouped rats. Pharmacol. Biochem. Behar/. 17,49–52 (1982).
  • Loscher W, Honack D. Valproate and its major metabolite e-2-en-valproate induce different effects on behavior and brain monoamine metabolism in rats. Eur Pharmacol. 299,61–67 (1996).
  • Biggs CS, Pearce BR, Fowler LJ, Whitton PS. The effect of sodium valproate on extracellular GABA and other amino acids in the rat ventral hippocampus — an in vivo microdialysis study. Brain Res. 594, 138–142 (1992).
  • Baf MHM, Subhash MN, Lakshmana KM, Rao BSSR. Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem. Int. 24, 67–72 (1994).
  • Takebayashi M, Motohashi N, Saito H, Kagaya A, Yamawaki S. Effect of acute treatment with sodium valproate on catecholamine and serotonin synthesis in mouse cerebral cortex. Neuropsychobiology 32,124–127 (1995).
  • Kanner AM, Balabanov A. Valproate: a practical review of its uses in neurological and psychiatric disorders. Expert Rev Neurotherapeutics2(2), 151–165 (2002).
  • Oluboka OJ, Bird DC, Kutcher S, Kusumakar V. A pilot study of loading versus titration of valproate in the treatment of acute mania. Bipolar Disord 4, 341–345 (2002).
  • Keck PE, McElroy SL, Tugrul KC, Bennett JA. Valproate oral loading in the treatment of acute mania. J. Clin. Psychiatry 54, 305–308 (1993).
  • McElroy SL, Keck PE Jr, Tugrul KC, Bennett JA. Valproate as a loading treating in acute mania. Neuropsychobiology27, 146–149 (1993).
  • McElroy SL, Keck PE Jr, Staton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex oral loading versus haldoperidol in the initial treatment of acute psychotic mania. j Clin. fiychMtry57,142–146 (1998).
  • •Demonstrates antipsychotic properties of divalproex in psychotic mania.
  • Pope HG, McElroy SL, Keck PE, Hudson JI. Valproate in the treatment of acute mania. Arch. Gen. Psychiatry 48,62–68 (1991).
  • Bowden CL, Janicak PG, Orsulak P et al. Relation of serum valproate concentration to response in mania. Am.j Psychiatry 153, 765–770 (1996).
  • Davis LL, Ambrose SA, Waldrop E et al. Switching to divalproex extended-release in patients with bipolar disorder. 156th Annual Meeting of the American Psychiatric Association. 18-22 May, CA, USA (2003).
  • Horn RL, Cunanan C. Safety and efficacy of switching psychiatric patients from a delayed--release to an extended—release formulation of divalproex sodium. J. Gun. fiychophatmacol. 232,1–6 (2003).
  • McElroy SL, Keck PE, Pope HG. Sodium valproate: its use in primary psychiatric disorders. J. Clin. Psychopharmacol. 7, 16–24 (1987).
  • Freeman TVV, Clotheir JL, Pazzaglia P. A double-blind comparison of valproic acid and lithium in the treatment of acute mania. Am. Psychiatty 149,12–21 (1992).
  • Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JA MA 271,918-924 (1994). Pivotal controlled study of divalproex for bipolar mania.
  • Bowden CL, Davis J, Morris D et al. Effect size of efficacy measures comparing divalproex, lithium and placebo in acute mania. Depress. Anxiety6(1), 26–30 (1997).
  • Swann AC, Bowden CL, Morris D et al. Depression during mania — treatment response to lithium or divalproex. Arch. Gen Psychiatry54, 37–42 (1997).
  • •Shows that divalproex is superior to lithium in treating dysphoric mania.
  • Swan AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Mania: differential effects of previous depressive and manic episodes on response to treatment. Acta Psychiatc Scam/. 101, 444–451 (2000).
  • •Shows that divalproex is superior to lithium for patients with high number of lifetime mood episodes.
  • Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Somerville KW A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder.j Clin. Ptychiatry12,1148–1155 (2002).
  • ••Head-to-head comparison of loading-dosedivalproex versus olanzapine for bipolar mania showing no significant differences in efficacy
  • Tohen M, Baker RVV, Altshuler LL et al. Olanzapine versus divalproex in the treatment of acute mania. Am. J. Psychiatry 6,1011–1017 (2002).
  • ••Head-to-head comparison showingolanzapine to be significantly better than &rated dose divalproex for reducing mania symptoms.
  • Vieta E. Divalproex versus olanzapine in mania. J. Clin. Psych. 64,1266–1267 (2003).
  • Revicki DA, Paramore LC, Sommerville KW, Swann AC, Zajecka JM, for the Depakote Comparator Study Group. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J. Clin. Psych. 64(3), 288–294 (2003).
  • Tohen M, Chengapa KNR, Suppes T et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. Ptychiatry59, 62–69 (2002).
  • ••Demonstrates that combination therapy isbetter than mood stabilizer monotherapy.
  • Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden C. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am. J. Psychiatry 159(7), 1146–1154 (2002). Demonstrates that combination therapy is better than mood stabilizer monotherapy.
  • Yatham UN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilizers plus risperidone or placebo in the treatment of acute mania. Br. fiychiatry182,141–147 (2003).
  • Muller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European valproate mania study group. J. Gun. Psychopharmacol 20,195–203 (2000).
  • Peet M. Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. BE j Psychiatry164, 549–550 (1994).
  • Franlde WG, Perlis RII, Deckersbach T et al. Bipolar depression: relationship between episode length and antidepressant treatment. Ptychol Med. 32,1417–1423 (2002).
  • Tohen M, Vieta E, Calabrese J et al Efficacy of olanzapine and olanzapine—fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Ptychiatryll, 1079–88 (2003).
  • Frye MA, Ketter TA, Kimbrell TA et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. Ptychophalmacol 20,607–614 (2000).
  • Petty F, Kram M, Davis LL et al. Valproate treatment of bipolar depression. Proceedings of 39th Annual NCDEU Meeting. FL, USA (1999).
  • Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am. J. Psychiatry 157,124–126 (2000).
  • Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. j Clin. PTchopharmacol 12\(Suppl. 1), S53—S56 (1992).
  • Winsberg ME, DeGolia SG, Strong CM, Ketter TA. Divalproex therapy in medication-naive and mood stabilizer-naive bipolar II depression. J. Affect. Disold 67, 207–212 (2001).
  • Gyulai L, Bowden CL, McElroy SL et al Maintenance efficacy of divalproex in the prevention of bipolar depression. Neumpsychophatmacology28,1374–1382 (2003).
  • Tohen M, Ketter, T, Zarate CA et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J. Psychiatry 160(7), 1263–1271 (2003).
  • Calabrese JR, Shelton MD, Rapport DJ, Kujawa M, Kimmel SE, Caban S. Current research on rapid cycling bipolar disorder and its treatment. J. Affect. Disold 67, 241–255 (2001).
  • Calabrese JR, Woyshville, MJ, Kimmal SE, Rapport DJ. Predictors of valproate response in bipolar rapid cycling. J. Clin. Psychopharmacol 13,280–283 (1993).
  • McElroy SL, Keck PE Jr, Strakowski SM. An overview of the treatment of schizoaffective disorder. J. Clin. Psych. 60\(Suppl. 5), 16–21 (1999).
  • McElroy SL, Keck, Jr PE, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. j Clin. Psychiatry59, 142–146 (1996).
  • Citrome L, Levin J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994–1998. Psychiatry Serv 51, 634–638 (2000).
  • Wassef AA, Dott SG, Harris A, Brown A, O'Boyle M, Meyer III WJ. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. Clin. PTchopharmacol 20,357–361 (2000).
  • Casey DE, Daniel DG, Wassef AA, Tracy IKA, Wozniak P, Somerville KW Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychophatmacology28,182–192 (2003).
  • •• Pivotal controlled trial demonstrating combination therapy better than antipsychotic monotherapy in treatment of acute exacerbation of schizophrenia.
  • Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychophatmacology26 (4), 530–536 (2002).
  • Donovan SJ, Stewart JW, Nunes EV et al Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. AM. I fiychiatry157,818–820 (2000).
  • Hollander E, Allen A, Lopez RP et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J. Clin. Psych. 62(3), 199–203 (2001).
  • Hollander E, Tracy IKA, Swann AC et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychophatmacology28 (6), 1186–1197 (2003).
  • Hollander E, Swann A, Coccaro EF et al Divalproex sodium is superior to placebo for impulsive aggression in cluster B personality disorders. 155th Annual Meeting of the American Psychiatric Association.18-23 May, PA, USA (2002).
  • Petty F, Davis L, Nugent AL et al Valproate therapy for chronic, combat-induced post-traumatic stress disorder. J. Clin. PTchopharmacol 22(1), 100–101 (2002).
  • •Largest open-label trial of divalproex for post-traumatic stress disorder.
  • Fesler FA. Valproate in combat-related post-traumatic stress disorder. J. Clin. PTchiatry52, S361 (1991).
  • Goldberg JF, Whitney P, Whiteside JE, Cloitre M, Davis LL, Hyemee H. Divalproex in PTSD resulting from sexual abuse. American Psychiatric Association Annual Meeting: 15-20 May, Washington DC, USA (1999).
  • Clark RD, Canive JM, Calais LA, Qualls CR, Tuason VB. Divalproex in post-traumatic stress disorder: an open label clinical trial. j Traumatic Stress 12(2), 395–401 (1999).
  • Brady KT, Sonne S, Anton R, Ballenger JC. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J. Clin. Psych. 56, 118–121 (1995).
  • Hertzman M. Divalproex sodium to treatment concomitant substance abuse and mood disorders. .1. Subst. Abuse Treat 18, 371–372 (2000).
  • Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. A history of substance abuse complicates remission from acute mania in bipolar disorder. j din. Psych. 60, 733–740 (1999).
  • Brady KT, Myrick H, Henderson S, Coffey SF. The use of divalproex in alcohol relapse prevention: a pilot study. Thug Alcohol Depend. 67(3), 323–330 (2002).
  • Freeman MP, Freeman SA, McElroy. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J. Affect. Disold 68,1–23 (2002).
  • Sachs GS, Thase ME, Otto MW et al. Rational, Design and Methods of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol. Psychiatry 53,1028–1042 (2003).
  • ••An ongoing national, longitudinal publichealth initiative, which examines the effectiveness of treatments for bipolar disorder, sponsored by the National Institute of Mental Health.
  • Li X, Ketter TA, Frye MA. Synaptic, intracellular and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders?' Affect. Disold 69,1–14 (2002).
  • Silverstone PH, Wu RII, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC. Chronic treatment with lithium, but not sodium valproate, increases cortical .X acetyl-aspartate concentrations in euthymic bipolar patients. Int. Clin. PTchophalmacol.18, 73–79 (2003).
  • Hennion JP, el-Marsri MA, Huff Mo, el-Mailakh RS. Evaluation of neuroprotection by lithium and valproic acid against ouabain-induced cell damage. Bipolar Disord 4,201–206 (2002).
  • Mom A, Gonzalez-Polo RA, Fuentes JM, Soler G, Centeno F. Different mechanisms of protection against apoptosis by valproate and Lit Eur Biochem. 266,886–891 (1999).
  • Loy R, Tariot PN. Neuroprotective properties of valproate: potential benefit for AD and taupathies. j Mal Neurosci 19, 303–307 (2002).
  • Tariot PN, Loy R, Ryan JM, Porsteinsson A, Ismail S. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Adv. Drug Deily. Rev 54, 1567–1577 (2002).
  • Isoherranen N, Yagen B, Bialer M. New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? G117: Opin. Neuro1.16, 203–211 (2003) .

Website

  • National Institute of Mental Health. Mental Dixon:leis in America. Bethesda, MD: National Institute of Mental Health. NIH publication No. 01–4584 (2001). www.nimh.nih.gov/publicat/numbers.cfm (Accessed April 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.